Merck KGaA, Pfizer, Syndax to collaborate on combination ovarian cancer treatment
German drugmaker Merck KGaA and U.S. drug giant Pfizer revealed this week that they are collaborating with Syndax Pharmaceuticals to investigate avelumab as a combination treatment for advanced ovarian cancer. Read More »